RE:RE:RE:Rebranding the Sort1Preeviously they have said enrollment would begin by the end of this quarter but they did not update that yesterday. I am interested in knowing how easy it will be for them to enroll six ovarian patients with the critereia in place for this protocol. Six patients does not seem like many but given the protocol, maybe it is hard to find those that fit the study's criteria? Since the study was paused, will patients who have other options tend to choose those ahead of TH-1902 this slowing enrollment? I don't really know - it might be that with the investigators likely bought in to the new trial, they will each quickly have a patient or two enrolled.
I suppose there could be other corporate developments which could move the stock but, in the end, the stock will likely only have a big move higher if they are able to report good news on TH-1902's restarted trial and/or partnerships. So, while there will be news on the convert reetirement and sales of the legacy drug, that is not likely to be very significant.
Trogarzon wrote: What next. When will they restart enrolment of their 6 patients. I only heard Dubuc say see you on the next quarterly call. The next thing is the maturing 27.5M at 5.75% replaced by 15% credit card money. Not much to get excited about until somthing occurs. It does get our hopes for Th1902 back on the science level but it's all about money now and they are strangled by Marathon deal and covenants.